Search

Your search keyword '"Lasne D"' showing total 30 results
Start Over Author "Lasne D" Search Limiters Peer Reviewed
30 results on '"Lasne D"'

2. French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children

Author

Chauveau, D., Clouscard, J., Frere, C., Hachulla, E., Kone-Paut, I., Lasne, D., Lecompte, T., Le Guern, V., Ni Zard, J., Papo, T., Riviere, M., Schleinitz, N., Tossier, B., Amoura, Z., Bader-Meunier, B., BAL dit Sollier, C., Belot, A., Benhamou, Y., Bezanahary, H., Cohen, F., Costedoat-Chalumeau, N., Darnige, L., Drouet, L., Elefant, E., Harroche, A., Lambert, M., Martin, T., Martin-Toutain, I., Mathian, A., Mekinian, A., Pineton De Chambrun, M., de Pontual, L., Wahl, D., Yelnik, C., and Zuily, S.

Published
2023
Full Text
View/download PDF

3. Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021): From the French working group on perioperative haemostasis (GIHP) and the French study group on thrombosis and haemostasis (GFHT), in collaboration with the French society of anaesthesia and intensive care (SFAR)

Author

Albaladejo, P., Blais, N., Bonhomme, F., Borel-Derlon, A., Cohen, A., Collet, J.-P., de Maistre, E., Fontana, P., Garrigue Huet, D., Godier, A., Gruel, Y., Godon, A., Ickx, B., Laporte, S., Lasne, D., Llau, J., Le Gal, G., Lecompte, T., Lessire, S., Levy, J.H., Longrois, D., Madi-Jebara, S., Mansour, A., Mazighi, M., Mismetti, P., Morange, P.E., Motte, S., Mullier, F., Nathan, N., Nguyen, P., Pernod, G., Rosencher, N., Roullet, S., Roy, P.M., Schlumberger, S., Sié, P., Steib, A., Susen, S., Tacquard, C.A., Testa, S., Vincentelli, A., Zufferey, P., Boissier, E, Dumont, B, James, C, Siguret, V., Godon, Alexandre, Tacquard, Charles Ambroise, Mansour, Alexandre, Garrigue, Delphine, Nguyen, Philippe, Lasne, Dominique, Testa, Sophie, Levy, Jerrold H., Albaladejo, Pierre, Gruel, Yves, Susen, Sophie, and Godier, Anne

Published
2021
Full Text
View/download PDF

4. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia

Author

Albaladejo, P., Blais, N., Bonhomme, F., Borel-Derlon, A., Cohen, A., Collet, J.-P., de Maistre, E., Fontana, P., Garrigue Huet, D., Godier, A., Gruel, Y., Godon, A., Ickx, B., Laporte, S., Lasne, D., Llau, J., Le Gal, G., Lecompte, T., Lessire, S., Levy, J.H., Longrois, D., Madi-Jebara, S., Mansour, A., Mazighi, M., Mismetti, P., Morange, P.E., Motte, S., Mullier, F., Nathan, N., Nguyen, P., Pernod, G., Rosencher, N., Roullet, S., Roy, P.M., Schlumberger, S., Sié, P., Steib, A., Susen, S., Tacquard, C.A., Testa, S., Vincentelli, A., Zufferey, P., Tacquard, Charles, Mansour, Alexandre, Godon, Alexandre, Godet, Julien, Poissy, Julien, Garrigue, Delphine, Kipnis, Eric, Rym Hamada, Sophie, Mertes, Paul Michel, Steib, Annick, Ulliel-Roche, Mathilde, Bouhemad, Bélaïd, Nguyen, Maxime, Reizine, Florian, Gouin-Thibault, Isabelle, Besse, Marie Charlotte, Collercandy, Nived, Mankikian, Stefan, Levy, Jerrold H., Gruel, Yves, Albaladejo, Pierre, Susen, Sophie, and Godier, Anne

Published
2021
Full Text
View/download PDF

5. Diagnosis and management of heparin-induced thrombocytopenia

Author

Albaladejo, P., Belisle, S., Blais, N., Bonhomme, F., Borel-Derlon, A., Borg, J.Y., Bosson, J.-L., Cohen, A., Collet, J.-P., de Maistre, E., Faraoni, D., Fontana, P., Huet, D. Garrigue, Godier, A., Gruel, Y., Guay, J., Hardy, J.F., Huet, Y., Ickx, B., Laporte, S., Lasne, D., Levy, J.H., Llau, J., Le Gal, G., Lecompte, T., Lessire, S., Longrois, D., Madi-Jebara, S., Marret, E., Mas, J.L., Mazighi, M., Meyer, G., Mismetti, P., Morange, P.E., Motte, S., Mullier, F., Nathan, N., Nguyen, P., Ozier, Y., Pernod, G., Rosencher, N., Roullet, S., Roy, P.M., Samama, C.M., Schlumberger, S., Schved, J.F., Sié, P., Steib, A., Susen, S., Testa, S., van Belle, E., van Der Linden, P., Vincentelli, A., Zufferey, P., Gruel, Yves, De Maistre, Emmanuel, Pouplard, Claire, Mullier, François, Susen, Sophie, Roullet, Stéphanie, Blais, Normand, Le Gal, Grégoire, Vincentelli, André, Lasne, Dominique, Lecompte, Thomas, Albaladejo, Pierre, and Godier, Anne

Published
2020
Full Text
View/download PDF

7. Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR)

Author

Albaladejo, P., Belisle, S., Blais, N., Bonhomme, F., Borel-Derlon, A., Borg, J.Y., Bosson, J.-L., Cohen, A., Collet, J.-P., de Maistre, E., Faraoni, D., Fontana, P., Garrigue Huet, D., Godier, A., Gruel, Y., Guay, J., Hardy, J.F., Huet, Y., Ickx, B., Laporte, S., Lasne, D., Levy, J.H., Llau, J., Le Gal, G., Lecompte, T., Lessire, S., Longrois, D., Madi-Jebara, S., Marret, E., Mas, J.L., Mazighi, M., Mismetti, P., Morange, P.E., Motte, S., Mullier, F., Nathan, N., Nguyen, P., Ozier, Y., Pernod, G., Rosencher, N., Roullet, S., Roy, P.M., Samama, C.M., Schlumberger, S., Schved, J.F., Sié, P., Steib, A., Susen, S., van Belle, E., van Der Linden, P., Vincentelli, A., Zufferey, P., Godier, Anne, Fontana, Pierre, Motte, Serge, Steib, Annick, Bonhomme, Fanny, Schlumberger, Sylvie, Lecompte, Thomas, Rosencher, Nadia, Susen, Sophie, Vincentelli, André, Gruel, Yves, Albaladejo, Pierre, and Collet, Jean-Philippe

Published
2018
Full Text
View/download PDF

8. Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR)

Author

Albaladejo, P., Belisle, S., Blais, N., Bonhomme, F., Borel-Derlon, A., Borg, J.Y., Bosson, J.-L., Cohen, A., Collet, J.-P., de Maistre, E., Faraoni, D., Fontana, P., Garrigue Huet, D., Godier, A., Gruel, Y., Guay, J., Hardy, J.F., Huet, Y., Ickx, B., Laporte, S., Lasne, D., Levy, J.H., Llau, J., Le Gal, G., Lecompte, T., Lessire, S., Longrois, D., Madi-Jebara, S., Marret, E., Mas, J.L., Mazighi, M., Mismetti, P., Morange, P.E., Motte, S., Mullier, F., Nathan, N., Nguyen, P., Ozier, Y., Pernod, G., Rosencher, N., Roullet, S., Roy, P.M., Samama, C.M., Schlumberger, S., Schved, J.F., Sié, P., Steib, A., Susen, S., van Belle, E., van Der Linden, P., Vincentelli, A., Zufferey, P., Godier, Anne, Fontana, Pierre, Motte, Serge, Steib, Annick, Bonhomme, Fanny, Schlumberger, Sylvie, Lecompte, Thomas, Rosencher, Nadia, Susen, Sophie, Vincentelli, André, Gruel, Yves, Albaladejo, Pierre, and Collet, Jean-Philippe

Published
2018
Full Text
View/download PDF

24. Agreement between factor XIII activity and antigen assays in measurement of factor XIII: A French multicenter study of 147 human plasma samples.

Author

Caron, C., Meley, R., Le Cam Duchez, V., Aillaud, M. F., Lavenu‐Bombled, C., Dutrillaux, F., Flaujac, C., Ryman, A., Ternisien, C., Lasne, D., Galinat, H., and Pouplard, C.

Subjects
BLOOD coagulation disorders, GENETIC disorder diagnosis, ANTIGENS, BLOOD coagulation factors, BLOOD plasma, IMMUNOASSAY, MEDICAL cooperation, PATHOLOGICAL laboratories, PROBABILITY theory, RESEARCH, RESEARCH evaluation, DIAGNOSIS
Abstract

Introduction Factor XIII ( FXIII) deficiency is a rare hemorrhagic disorder whose early diagnosis is crucial for appropriate treatment and prophylactic supplementation in cases of severe deficiency. International guidelines recommend a quantitative FXIII activity assay as first-line screening test. FXIII antigen measurement may be performed to establish the subtype of FXIII deficiency ( FXIIID) when activity is decreased. Methods The aim of this multicenter study was to evaluate the analytical and diagnostic levels of performance of a new latex immunoassay, K-Assay® FXIII reagent from Stago, for first-line measurement of FXIII antigen. Results were compared to those obtained with the Berichrom® FXIII chromogenic assay for measurement of FXIII activity. Of the 147 patient plasma samples, 138 were selected for analysis. Results The accuracy was very good, with intercenter reproducibility close to 7%. Five groups were defined on FXIII activity level (<5% ( n = 5), 5%-30% ( n = 23), 30%-60% ( n = 17), 60%-120% ( n = 69), above 120% ( n = 24)), without statistical differences between activity and antigen levels ( P value >0.05). Correlation of the K-Assay® with the Berichrom® FXIII activity results was excellent (r = 0.919). Good agreement was established by the Bland and Altman method, with a bias of +9.4% on all samples, and of −1.4% for FXIII levels lower than 30%. One patient with afibrinogenemia showed low levels of Berichrom® FXIII activity but normal antigen level and clot solubility as expected. Conclusions The measurement of FXIII antigen using the K-Assay® is a reliable first-line tool for detection of FXIII deficiency when an activity assay is not available. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

25. Severe adverse events related to vitamin K antagonists in children with congenital or acquired heart disease.

Author

Bajolle, F., Derridj, N., Bitan, J., Ndjoli, H., Lasne, D., and Bonnet, D.

Abstract

Although increasingly used, vitamin K antagonists (VKA) remain difficult to manage for children with congenital or acquired heart disease (CAHD). To assess the occurrence of thrombosis and major bleeding events in children with CAHD treated with VKA and to determine associated risk factors. All children enrolled in the VKA dedicated educational program between 2008 and 2020 were prospectively included. Clinically suspected thrombotic events were confirmed by imaging, while major bleedings were defined according to the ISTH. Time in therapeutic range (TTR) was calculated to evaluate the stability of anticoagulant therapy. Statistical analysis included Cox proportional hazard models. We included 390 patients, median age at initiation was 6.6 (IQR: 12.8–3.2) years. Median follow-up was 17.7 months. The median TTR was 85.2% (IQR: 95.3%–74.4%). Thirteen thrombosis in 9 (2.3%) children and 24 major bleedings in 17 (4.4%) children were reported. At 6 years, 86.6% (CI95% [75.6%–92.4%]) and 95% (CI95% [89%–97.8%]) of patients were free of major bleeding and thrombotic events, respectively. In univariate analysis mitral valve replacement (MVR) was associated to major bleeding events (HR 3.32 [1.16–9.44], P = 0.025). In multivariable analysis, recurrent minor bleeding events (≥ 3) (HR 4.9 [1.7–13.8], P = 0.002) and global TTR under 70% (HR: 3.6 [1.1–10.9], P = 0.04) were risk factors associated to major bleeding events whereas MVR did not reach the level of significant association (HR: 1.92 [0.6; 5.9], P = 0.25). In multivariable analysis, Kawasaki disease (HR: 11.84 [2.7–52.6], P = 0.001) and global TTR under 80% (HR: 5.05 [1.2–20.7], P = 0.025) were main risk factors for thrombotic events. Overall, VKA use appears to be safe and effective in children with CAHD. Patients with Kawasaki disease and those with a TTR under 80% are at highest risk of thrombosis. A TTR under 70% and minor recurrent bleeding events are the main risk factors for major bleeding events. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Molecular diagnosis of haemophilia A in patients from Senegal.

Author

Seck, M., Costa, C., Faye, B. F., Sy Bah, D., Touré, S. A., Dieng, N., Sall, A., Gadji, M., Touré, A. O., Lasne, D., Rothschild, C., and Diop, S.

Subjects
HEMOPHILIA, BLOOD coagulation disorders, BLOOD diseases, BLOOD disease treatment, GENETIC epidemiology, DIAGNOSIS, GENETICS
Abstract

The article discusses a study on the molecular diagnosis of haemophilia A in patients from Senegal. It highlights the significance of identifying molecular variations of the F8 gene in a hemophilia population, risk factors for developing FVIII inhibitors, and frequency of carrier status in patients' families.

Published
2017
Full Text
View/download PDF

27. Discrepancies between one stage assay and chromogenic substrate assay in patients treated with recombinant or plasma-derived FVIII and usefulness of a specific standard in ReFacto AF®-treated patients.

Author

Pouplard, C., Ternisien, C., Desconclois, C., Lasne, D., Aillaud, M.‐F., and Caron, C.

Subjects
CHROMOGENIC compounds, BLOOD coagulation factor VIII, HEMOPHILIACS, BLOOD plasma, PHARMACOKINETICS
Abstract

The article offers information on a study conducted by the authors on discrepancies between chromogenic substrate assay and one stage assay in patients who are treated with coagulation factor VIII. Topics discussed include evaluation of the ReFacto antihemophilic factor in clinical practice, testing of plasma samples of the patients, and mentions the need for guidelines to be followed for postinfusion monitoring and pharmacokinetic assessment of coagulation factor FVIII concentrates.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results